

Accepted Manuscript

Title: Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Authors: Devendra Hiwase, Peter Tan, James D'Rozario, John Taper, Anthony Powell, Ian Irving, Matthew Wright, Susan Branford, David T. Yeung, Luke Anderson, Othon Gervasio, Carly Levetan, Will Roberts, Ann Solterbeck, Robert Traficante, Timothy Hughes


PII: S0145-2126(18)30048-1
DOI: <https://doi.org/10.1016/j.leukres.2018.02.013>
Reference: LR 5921

To appear in: *Leukemia Research*

Received date: 10-8-2017
Revised date: 13-2-2018
Accepted date: 19-2-2018

Please cite this article as: Hiwase Devendra, Tan Peter, D'Rozario James, Taper John, Powell Anthony, Irving Ian, Wright Matthew, Branford Susan, Yeung David T, Anderson Luke, Gervasio Othon, Levetan Carly, Roberts Will, Solterbeck Ann, Traficante Robert, Hughes Timothy. Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. *Leukemia Research* <https://doi.org/10.1016/j.leukres.2018.02.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Authors: Devendra Hiwase,¹ Peter Tan,² James D’Rozario,³ John Taper,⁴ Anthony Powell,⁵ Ian Irving,⁶ Matthew Wright,⁷ Susan Branford,⁸ David T Yeung,⁹ Luke Anderson,¹⁰ Othon Gervasio,¹⁰ Carly Levetan,¹⁰ Will Roberts,¹¹ Ann Solterbeck,¹² Robert Traficante,¹² Timothy Hughes⁹

Affiliations: ¹Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; ²Perth Blood Institute, Nedlands, Perth, Australia; ³Australian National University Medical School, Canberra, Australia; ⁴Haematology, Nepean Hospital, Kingswood, Australia; ⁵Haematology, Nambour General Hospital, Nambour, Australia; ⁶Icon Cancer Care Wesley, Brisbane, Australia; ⁷Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia; ⁸Department of Genetics and Molecular Pathology and Centre for Cancer Biology, SA Pathology, Adelaide, Australia; ⁹Haematology Division, Royal Adelaide Hospital, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia; ¹⁰Novartis Pharmaceuticals, Sydney, Australia; ¹¹Novartis Pharmaceuticals UK Ltd, Camberley, UK; ¹²Statistical Revelations, Melbourne, Australia

Corresponding author: Professor Timothy Hughes, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia. Email: tim.hughes@sahmri.com.

Authors: Devendra Hiwase,¹ Peter Tan,² James D’Rozario,³ John Taper,⁴ Anthony Powell,⁵ Ian Irving,⁶ Matthew Wright,⁷ Susan Branford,⁸ David T Yeung,⁹ Luke Anderson,¹⁰ Othon Gervasio,¹⁰ Carly Levetan,¹⁰ Will Roberts,¹¹ Ann Solterbeck,¹² Robert Traficante,¹² Timothy Hughes⁹

Corresponding author: Professor Timothy Hughes, University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia. Email: tim.hughes@sahmri.com.

LR-D-17-00289

Highlights

- Treatment of CML-CP with a TKI may lead to intolerable adverse events
- Switching to an alternative TKI is an option
- 20 CML-CP patients intolerant of imatinib or dasatinib switched to nilotinib
- 50% of patients achieved MR4.5 at any timepoint up to month 24
- Nilotinib showed minimal cross intolerance

Download English Version:

<https://daneshyari.com/en/article/8453365>

Download Persian Version:

<https://daneshyari.com/article/8453365>

[Daneshyari.com](https://daneshyari.com)